The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

AdChoices
 

Merrimack Pharmaceuticals Inc

Nasdaq: MACK
Last

(U.S.) $6.67

Today's change+0.36 +5.71%
Updated May 31 4:00 PM -4GMT. Delayed by at least 15 minutes.
 

Merrimack Pharmaceuticals Inc

Nasdaq: MACK
Last

(U.S.) $6.67

Today's change+0.36 +5.71%
Updated May 31 4:00 PM -4GMT. Delayed by at least 15 minutes.

Merrimack Pharmaceuticals Inc crosses above 20-day moving average

Merrimack Pharmaceuticals Inc closed up sharply Tuesday, rallying (U.S.)$0.36 or 5.71% to (U.S.)$6.67 and crossing above its 20-day moving average. Over the last five days, shares have lost 3.61% and are down 15.57% for the last year to date. This security has underperformed the S&P 500 by 42.98% during the last year.

Key company metrics

  • Open(U.S.) $6.35
  • Previous close(U.S.) $6.31
  • High(U.S.) $6.71
  • Low(U.S.) $6.29
  • Bid / Ask(U.S.) $6.36 / (U.S.) $6.82
  • YTD % change-15.57%
  • Volume3,117,389
  • Average volume (10-day)1,849,812
  • Average volume (1-month)1,816,633
  • Average volume (3-month)1,937,858
  • 52-week range(U.S.) $5.02 to (U.S.) $13.00
  • Beta1.93
  • Trailing P/ENegative, not meaningful
  • P/E 1 year forwardNegative, not meaningful
  • Forward PEGNegative, not meaningful
  • Indicated annual dividend--
  • Dividend yield0.00%
  • Trailing EPS(U.S.) -$1.33
Updated May 31 4:00 PM -4GMT. Delayed by at least 15 minutes.
S&P TSX0.15%Sector:HealthcareIndustry:Biotechnology

Latest Company News

    No News Results.
  • Income Statement
  • Balance Sheet
  • Cash Flow
Quarter | Annual
Q1/2016Q4/2015Q3/2015Q2/2015
Fiscal Quarter Endvalues in (U.S.) $ millions unless otherwise notedMar 31, 201603/31/2016Dec 31, 201512/31/2015Sep 30, 201509/30/2015Jun 30, 201506/30/2015
Revenue21211637
Total other revenue--------
Total revenue21211637
Gross profit2121----
Total cost of revenue10----
Total operating expense51645555
Selling / general / administrative18191712
Research & development33453843
Depreciation / amortization--------
Interest expense (income), net operating--------
Unusual expense (income)--------
Other operating expenses, total--------
Operating income-30-43-38-19
Interest income (expense), net non-operating-9-6-4-4
Gain (loss) on sale of assets--------
Other--------
Income before tax-39-48-42-23
Income after tax-39-48-42-23
Income tax, total--------
Net income-38-48-43-23
Total adjustments to net income--------
Net income before extra. items-38-48-43-23
Minority interest0000
Equity in affiliates--------
U.S. GAAP adjustment--------
Inc. avail. to common excl. extra. items-38-48-43-23
Inc. avail. to common incl. extra. items-38-48-43-23
Diluted net income-38-48-43-23
Dilution adjustment--0----
Diluted weighted average shares116116112110
Diluted EPS excluding extraordinary itemsvalue per share-0.33-0.41-0.38-0.21
Dividends per sharevalue per share0.000.000.000.00
Diluted normalized EPSvalue per share-0.33-0.41-0.38-0.21
R